Search research articles
Contact Us
Filters
Showing results (111-120 of 126) with videos related to
Page
of 13
Sort By:
Journal for Immunotherapy of Cancer
|
March 17, 2022
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Safae Terrisse, Anne-Gaelle Goubet, Kousuke Ueda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects
Carolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Science (New York, N.Y.)
|
November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Nature Medicine
|
February 4, 2022
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Nature Medicine
|
July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Bertrand Routy, John G Lenehan, Wilson H Miller, et al.
Nature Medicine
|
May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
Maria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
EMBO Molecular Medicine
|
December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncology
Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Cancer Discovery
|
December 21, 2021
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis
Satoru Yonekura, Safae Terrisse, Carolina Alves Costa Silva, et al.
Nature Medicine
|
January 28, 2026
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
Sreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, et al.
Science (New York, N.Y.)
|
November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 126) with videos related to
Sort By:
Page
of 13
Journal for Immunotherapy of Cancer
|
March 17, 2022
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Safae Terrisse, Anne-Gaelle Goubet, Kousuke Ueda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects
Carolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Science (New York, N.Y.)
|
November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Nature Medicine
|
February 4, 2022
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Nature Medicine
|
July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Bertrand Routy, John G Lenehan, Wilson H Miller, et al.
Nature Medicine
|
May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
Maria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
EMBO Molecular Medicine
|
December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncology
Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Cancer Discovery
|
December 21, 2021
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis
Satoru Yonekura, Safae Terrisse, Carolina Alves Costa Silva, et al.
Nature Medicine
|
January 28, 2026
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
Sreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, et al.
Science (New York, N.Y.)
|
November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Page
of 13